Copyright 2009 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Restrictions Apply to Government Use.2009
The Cutting Edge article by Muñtos-Santos et al,1 “Response of Keratosis Lichenoides Chronica to Efalizumab Therapy,” published in the August 2009 issue of the Archives, was accepted on August 12, 2008, which is prior to the recognition of the safety concerns of efalizumab. As noted by Korman et al2 in the commentary in the same issue, reports of progressive multifocal leukoencephalopathy (PML) in patients treated with efalizumab in the absence of other immunosuppressive agents led the manufacturers to voluntarily withdraw the drug from the market.
Linking Publication About Efalizumab Effectiveness With Safety Concerns. Arch Dermatol. 2009;145(11):1338. doi:10.1001/archdermatol.2009.295
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: